Rocio Dominguez Vidana, PhD
Rocio Dominguez Vidana, PhD
Verified email at bcm.edu
Title
Cited by
Cited by
Year
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
JD Kessler, KT Kahle, T Sun, KL Meerbrey, MR Schlabach, EM Schmitt, ...
Science Signalling 335 (6066), 348, 2012
3402012
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
TYT Hsu, LM Simon, NJ Neill, R Marcotte, A Sayad, CS Bland, ...
Nature 525 (7569), 384-388, 2015
2582015
Recurrent DNA inversion rearrangements in the human genome
M Flores, L Morales, C Gonzaga-Jauregui, R Domínguez-Vidaña, ...
Proceedings of the National Academy of Sciences 104 (15), 6099-6106, 2007
932007
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer
A Nair, HC Chung, T Sun, S Tyagi, LE Dobrolecki, R Dominguez-Vidana, ...
Nature medicine 24 (4), 505, 2018
212018
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor
KL Karlin, G Mondal, JK Hartman, S Tyagi, SJ Kurley, CS Bland, TYT Hsu, ...
Cell reports 9 (4), 1318-1332, 2014
162014
Identical repeated backbone of the human genome
CJ Zepeda-Mendoza, T Lemus, O Yáñez, D García, D Valle-García, ...
BMC genomics 11 (1), 60, 2010
52010
Abstract A05: The tumor suppressor function of Plk2 in triple-negative breast cancer may be mediated through regulation of Plk1
D Acosta, E Villegas, E Kabotyanski, C Montemayor, SJ Kurley, ...
Molecular Cancer Research 14 (2 Supplement), A05-A05, 2016
2016
Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies
RJ Bernardi, R Dominguez-Vidana, CS Bland, KA Scorsone, S Tyagi, ...
Cancer Research 75 (15 Supplement), 738-738, 2015
2015
PMCID: PMC3522262.
XQ SO, MZ Li, ZC Hartman, M Rao, P Yu, R Dominguez-Vidana, AC Liang, ...
Retrovirology 5, 72, 2008
2008
The system can't perform the operation now. Try again later.
Articles 1–9